[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer]

Chang Qi1, Panwen Tian1,2, Weimin Li1,3,4

  • 1Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China.

Summary

Neoadjuvant immunotherapy using immune checkpoint inhibitors (ICIs) shows promise for resectable non-small cell lung cancer (NSCLC). This review explores recent advancements, benefits, and challenges of neoadjuvant immunotherapy in NSCLC treatment.

Related Concept Videos